期刊文献+

阶梯式治疗慢性前列腺炎/慢性盆底疼痛综合征的疗效观察(附147例报告)

Study on treatment of chronic prostatitis / chronic pelvic pain syndrome using stepwise therapy (report of 147 cases)
原文传递
导出
摘要 目的探索慢性前列腺炎/慢性盆底疼痛综合征的阶梯式治疗手段的结果。方法全部147例病人使用慢性前列腺炎症状积分指数(NIH—CPSI)评分和SGA(全球主观症状评估)评分进行评估,治疗方法依次为:抗生素、抗炎药、α受体阻滞剂和抗焦虑抑郁药。结果患者平均年龄42岁,病程平均1.6年。根据尿与前列腺液的培养和常规检查,11.8%为Ⅱ型前列腺炎;另外88.2%是Ⅲ型前列腺炎,这其中42.4%属于Ⅲa,其余45.8%属于Ⅲb。这些病人(147例)的NIH—CPSI评分从最初的(23.2±5.6)下降到(12.5±8.7)(P〈0.001),根据SGA评分,其中82%为好转,12%无变化,6%恶化。结论阶梯式应用抗生素、抗炎药、CI受体阻滞剂和抗焦虑抑郁药可以成功地治愈绝大多数的慢性前列腺炎/慢性盆底疼痛综合症的病人。 Objective To evaluate the treatment of chronic prostatitis/chronic pelvic pain syndrome using stepwise therapy. Methods A total of 271 patients were assessed by the NIH-CPSI and SGA. The sequence modality therapy was as follow: antibiotics, anti-inflammatory phytotherapy, a -blockers and antianxiety & antidepressant. Results Mean age of patients was 42 years old and median symptom history was 1.6 years. Based on results of bacterial culture and routine examination of urine and prostatic fluid, 11.8% of the cases were type II prostatitis, other 88.2% were type Ⅲ prostatitis including 42.4% type Ⅲ and 45.8% Ⅲb. The score on the NIH-CPSI were changed from (23.2±5.6) to (12.5±8.7) (P〈0.001). Based on SGA score, 82% of the cases were better, 12% were the same and 6% were worse. Conclusion Stepwise modality therapy with antibiotics, anti-inflammatory phytotherapy, a -blockers and antianxiety & antidepressant was effective for treatment of most patients with chronic prostatitis/chronic pelvic pain syndrome.
出处 《中国男科学杂志》 CAS CSCD 2011年第4期23-26,共4页 Chinese Journal of Andrology
关键词 慢性前列腺炎/慢性盆底疼痛综合症 治疗结果 chronic prostatitis/chronic pelvic pain syndrome treatment outcome
  • 相关文献

参考文献14

  • 1Roberts RO, Lieber MM, Rhodes T, et al. Prevalence of a physicianassigned diagnosis of prostatitis: the Olmsted County study of urinary symptoms and health status among men. Urology 1998; 51(4): 578.
  • 2Litwin MS, McNaughton-Collins M, Fowler FJ, et al. The national institutes of health chronic prostatitis symptom index: development and validation of a new outcome measure. J Urol 1999;162(2): 369-375.
  • 3Nickel JC, Downey J, Johnston B, et al. Predictors of Patient Response to Antibiotic Therapy for the Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Prospective Multicenter Clinical Trial. J Uro12001;165(5): 1539-1544.
  • 4John NK, Donald ER. Bacteria in The Chronic Prostatitis- Chronic Pelvic Pain Syndrome: Molecular Approaches to Critical Research Questions. J Urol 2002; 167(6): 2574-2583.
  • 5Shoskes DA, Zeitlin SI, Shahed A, et al. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo control trial. Urology 1999; 54(6): 960-963.
  • 6Nadler RB, Koch AE, Campbell PL, et al. Interleukin IL- Ibeta and TNF-alpha in prostatic secretions are indicators in the evaluation of men with chronic prostatitis. J Urol 2000;164(1): 214-218.
  • 7Galley HF, Nelson S J, Dubbels AM, et al. Effect of ciprofloxacin on the accumulation of interleukin-6, interleukin-8, and nitrite from a human endothelial cell model of sepsis. Crit Care Med 1997; 25(8): 1392.
  • 8Hochreiter WW, Nadler RB, Koch AE, et al. Diagnostic value of serial cytokine changes in expressed prostatic secretions. J Urol 2000;163(suppl): 24.
  • 9Suaudeau, C, Chait A, Cimetiere C, et al. Analgesic effects of antibiotics in rats. Pharmacol Biochem Behav 1993; 46(2): 361.
  • 10Ishigooka M, Nakada T, Hashimoto T, et al. Spinal substance P immunoreactivity is enhanced by acute chemical stimulation of the rat prostate. Urology 2002;59(1): 139.

二级参考文献34

  • 1谢辉,何秋香,黄慧聪,杨亦荣,朱启建,陈建欧,李澄棣,夏鹏,沈龙捷,王思齐.140例青年前列腺组织病理学研究[J].中华泌尿外科杂志,2006,27(11):755-757. 被引量:15
  • 2Krieger JN, Nyberg LJr, Nickel JC. NIH consensus definition and classification of prostatifis. JAMA 1999; 282(3): 236-237.
  • 3McNaughton Cllins M, Pontari MA, OLeary MP, et al Quality of life is impaired in men with chronic prostatitis: the Chronic Prostatitis Collaborative Research Network. J Gen Intern Med 2001; 16(10): 656-662.
  • 4Wenniger K, Heiman JR, Rothman I, et al. Sickness impact of chronic nonbacterial prostatitis and its correlates. J Urol 1996; 155(3): 965-968.
  • 5Litwin MS, McNaughton-Collins M, Fowler FJ Jr, et al. The National Institutes of Health chronic prostatitis symptom index:development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol 1999; 162(2): 369-375.
  • 6Collins MM, Stafford RS, O'Leary MP, et at How common is prostatitis? A national survey of physician visits. J Urol 1998; 159(4): 1224-1228.
  • 7Walz J, Perrotte P, Hutterer G, et al. Impact of chronic Prostatitis-like symptoms on the quality of life in a large group of men. BJU lnt 2007; 100(6): 1307-1311.
  • 8Nickle JC, Downey J, Hunter D, et al. Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis sympton index. Urol 2001; 165(3): 842-845.
  • 9Duloy AM, Calhoun EA, Clemens JQ, et al. Economic impact of chronic prostatitis. Curr Urol Rep 2007; 8(4): 336-339.
  • 10Pontari MA, McNaughton Collins M, O'Leary MP, et al. A case-control study of risk factors in men with chronic pelvic pain syndrome. BJU Int 2005; 96(4): 559-565.

共引文献92

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部